Electrophilic chelating agents for irreversible binding of metal chelates to engineered antibodies

A. J. Chmura, Brian D. Schmidt, Donald T. Corson, Stacey L. Traviglia, Claude F. Meares

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Radiolabeled monoclonal antibodies are widely used in the detection and treatment of cancer. However, several problems still prevent full clinical exploitation of these reagents. Low tumor/background ratios in radioimmunoscintigraphy and high background radioactivity in therapy are the foremost among these. The strategy of pretargeting which separates the tumor-targeting step from radiolocalization step may overcome these limitations. One pretargeting approach, based on the streptavidin-biotin system, has been demonstrated to successfully treat cancer in preclinical models (Proc. Natl. Acad. Sci. 97 (2000) 1802). In this report we describe the synthesis of several electrophilic chelates, designed for use in vivo. In this new pretargeting approach, we have used protein engineering to prepare an antibody that can bind selectively and irreversibly to certain of these metal chelates. This improves upon approaches based on the immunogenic protein streptavidin and the endogenous ligand biotin.

Original languageEnglish (US)
Pages (from-to)249-258
Number of pages10
JournalJournal of Controlled Release
Issue number1-3
StatePublished - Jan 17 2002


  • Indium-111
  • Pretargeting
  • Radioimmuno imaging
  • Radioimmunotherapy
  • Yttrium-90

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Electrophilic chelating agents for irreversible binding of metal chelates to engineered antibodies'. Together they form a unique fingerprint.

Cite this